LILLE, France, February 20, 2019 / B3C newswire / -- AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease and Progressive Supranuclear Palsy (PSP), announced today the successful completion of the latest phase 1 study regarding the effect of food intake for its drug candidate AZP2006.
The Phase 1 study was performed by analyzing the effect of food intake on the pharmacokinetic parameters following a single oral administration of AZP2006 to 14 healthy volunteers. The compound was well tolerated by all volunteers and its pharmacokinetics was moderately impacted following the absorption of a rich diet.
The first Phase I clinical studies done with 88 subjects had shown that after oral administration, AZP2006 was well absorbed by the intestine and well tolerated by healthy volunteers.
"AlzProtect, with this new success, has now all the elements necessary to apply for our next phase 2a study with PSP patients. The first patient recruitments will occur in 2019 " said Philippe Verwaerde, president and scientific director of AlzProtect.
Founded in 2007, AlzProtect is a French Lille-based company created by Dr. André Delacourte, one of the pioneers of research on Alzheimer's disease, and Dr. Patricia Melnyk, expert in medicinal chemistry, in collaboration with Lille 2 University. and INSERM. The company employs 8 people and is supported by BPI France, the National Research Agency and Eurasanté. AlzProtect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases.
AlzProtect has 4 international patent families covering the medicines it develops and their indications worldwide.
AlzProtect is developing a drug candidate, AZP2006, whose mode of action and effects are clearly different from products developed in the last 15 years by the pharmaceutical industry. The flagship product of AlzProtect, AZP2006, has an innovative mechanism of action: it is a bioavailable neurotrophic inducer. Unlike most products developed by the competition, AZP2006 targets all causes of neurodegeneration and is not only targeted at markers such as Abeta protein or Tau protein. AZP2006 has obtained the status of "orphan drug" in Europe (European Medicines Agency) and in the United States (Food and Drug Administration) in the indication of PSP. It has been tested in humans, 88 healthy subjects, in two phase I clinical trials and has demonstrated excellent tolerability, with no adverse effects.
About neurodegenerative diseases
With its compound AZP2006, AlzProtect mainly targets two neurodegenerative diseases: progressive supranuclear palsy (PSP) and Alzheimer's disease.
PSP is a tauopathy with predominant accumulation of Tau isoforms with four repeat motifs (4R). It is characterized by neurofibrillary degeneration and neuronal loss in the brainstem, basal ganglia, frontal motor and associative cortex. The disease causes brainstem damage that progressively affects balance, vision, mobility, swallowing and speech. The number of PSP cases in Europe and the United States is estimated at 30,000 and 25,000, respectively. The life expectancy in the patient with PSP is estimated between 5 and 7 years. There is no treatment, to date, to stop or slow down the disease.
Alzheimer's disease is the most common form of dementia with an estimated 47 million patients worldwide in 2017, a figure that should increase to 75 million by 2030 or even 132 million by 2050 , according to the 2017 World Alzheimer Report. The pharmacological targets are Abeta protein, Tau protein and neuroinflammation. There is currently no reliable early diagnosis or treatment that can change the course of this disease: it is a major public health issue.
Dr Philippe Verwaerde
+33 (0)9 72649757
Published by B3C newswire and shared through Newronic®